Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo (nivolumab) appears to be on course to a potential Indian debut, after a key local expert panel recommended the product for marketing.
A subject expert committee (SEC), which advises the Indian regulator on trial-related permissions as part of a layered approval process,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?